All Stories

  1. The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice
  2. Impact of vitamin D receptor polymorphisms in selected metabolic disorders
  3. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
  4. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program
  5. Age-Related Differences in the Role of Risk Factors for Ischemic Stroke
  6. De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
  7. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
  8. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  9. On the Need for a Paradigm Change in the Valuation of Concrete with Waste Materials Based on the Example of Concrete with Crumb Rubber
  10. Efficacy and safety of bempedoic acid in women with hypercholesterolemia: Pooled analyses from phase 3 trials
  11. Higher Plasma Levels of Valerate Produced by Gut Microbiota May Have a Beneficial Impact on Renal Function
  12. In Reply: ACEI and ARB — Each Unique RAAS Inhibitors
  13. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert ...
  14. Which Statin is Best for the Kidneys?
  15. Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention
  16. Can We Use mTOR Inhibitors for COVID-19 Therapy?
  17. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019
  18. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  19. Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fraction—Subanalysis of the TELEREH-HF Randomized Clinical Trial
  20. Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
  21. Contemporary Management of Dyslipidemia
  22. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise between EBM and possibilities in healthcare.
  23. The detrimental impact of elevated Ferritin to Iron ratio on in-hospital prognosis of patients with COVID-19
  24. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  25. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
  26. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
  27. Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases
  28. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study
  29. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  30. Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
  31. Protective role of nutraceuticals against myocarditis
  32. Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).
  33. Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study
  34. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials
  35. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
  36. The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis
  37. Implications of the 2021 ESC Cardiovascular Risk Classification among 283,000 European Immigrants Living in a Low-Risk Region: A Population-Based Analysis in Catalonia
  38. Sleep Duration May Not Have Any Effect on The Risk of Stroke: Insights from Mendelian Randomization and Prospective Cohort Studies
  39. Extreme cardiovascular risk—do we need a new risk category?
  40. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  41. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
  42. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes
  43. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
  44. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
  45. Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel
  46. The International Lipid Expert Panel (ILEP)—the role of ‘optimal’ collaboration in the effective diagnosis and treatment of lipid disorders
  47. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study
  48. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  49. Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis
  50. Harnessing polyphenol power by targeting eNOS for vascular diseases
  51. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  52. The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis
  53. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status
  54. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  55. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  56. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  57. Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey
  58. Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis
  59. Are risk-based LDL-c goals achieved in primary and secondary care in central and Eastern Europe? comparison with other Europe regions from the DA VINCI observational study
  60. Factors and Prognostic Significance of Impaired Exercise Tolerance in Women over 40 with Arterial Hypertension
  61. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  62. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies
  63. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  64. Is COVID-19 Another Case of Obesity Paradox? - Results from An International Ecological Study on behalf of the REPROGRAM Consortium Obesity
  65. COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study
  66. Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study
  67. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications
  68. Targeting AMPK by Statins: A Potential Therapeutic Approach
  69. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
  70. Antiarrhythmic effect of 9-week hybrid cardiac telerehabilitation - subanalysis of the TELEREHabilitation in Heart Failure patients - TELEREH-HF randomized clinical trial
  71. Omega-6 fatty acids and the Risk of Cardiovascular Disease: Insights from a Systematic Review and Meta-Analysis of Randomized Controlled Trials and a Mendelian Randomization Study.
  72. Foam Cells as Therapeutic Targets in Atherosclerosis with a Focus on the Regulatory Roles of Non-Coding RNAs
  73. Α higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality- insight from a US national survey
  74. Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice
  75. Renal Denervation for Uncontrolled and Resistant Hypertension: Systematic Review and Network Meta-Analysis of Randomized Trials
  76. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel
  77. An aetiology‐based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) trial
  78. Effects of statins on mitochondrial pathways
  79. Drucebo effect – the challenge we should all definitely face!
  80. Lipid-lowering therapies: Better together
  81. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants
  82. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
  83. New trends in the pharmacological intervention of PPARs in obesity: Role of natural and synthetic compounds_
  84. Longer sleep duration may negatively affect renal function
  85. Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19
  86. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  87. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  88. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
  89. Cholesterol in Relation to COVID-19: Should We Care about It?
  90. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  91. Epigenetics in atherosclerosis: key features and therapeutic implications
  92. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways
  93. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  94. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  95. Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
  96. An overview of statin-induced myopathy and perspectives for the future
  97. Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort
  98. Egg Intake: Getting the Balance Right!
  99. Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study
  100. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  101. Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
  102. Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017
  103. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels
  104. A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS EVALUATING RENAL DENERVATION FOR UNCONTROLLED AND RESISTANT HYPERTENSION
  105. Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies
  106. BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS
  107. EFFICACY AND SAFETY OF ALIROCUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDY
  108. Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure
  109. FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALS
  110. Incretins and microRNAs: Interactions and physiological relevance
  111. High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study
  112. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  113. LCZ696 (sacubitril/valsartan) for patients with heart failure
  114. Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
  115. Epidemiology of facial fractures: incidence, prevalence and years lived with disability estimates from the Global Burden of Disease 2017 study
  116. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders
  117. Effects of immunisation against PCSK9 in mice bearing melanoma
  118. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
  119. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
  120. Low-carbohydrate diet: forget restriction, replace with balance!
  121. Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study
  122. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
  123. Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies
  124. Ca2+ Flux: Searching for a Role in Efferocytosis of Apoptotic Cells in Atherosclerosis
  125. Statins and Lp(a): do not make perfect the enemy of excellent
  126. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study
  127. Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units
  128. Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology
  129. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  130. Genetic testing in familial hypercholesterolaemia: What does it add?
  131. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
  132. Modulation of microRNAs by aspirin in cardiovascular disease
  133. Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
  134. A review of gene- and cell-based therapies for familial hypercholesterolemia
  135. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent
  136. A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study
  137. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials
  138. Role of Geriatric Syndromes in the Management of Atrial Fibrillation in Older Adults: A Narrative Review
  139. Dietary natural products as emerging lipoprotein(a)‐lowering agents
  140. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  141. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients
  142. A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations
  143. High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art
  144. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016
  145. Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth
  146. Link between plasma trans-fatty acid and fatty liver is moderated by adiposity
  147. Consumption of dairy product and its association with total and cause specific mortality – A population-based cohort study and meta-analysis
  148. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score
  149. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials
  150. MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy
  151. Natural products for targeted therapy in precision medicine
  152. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  153. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  154. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  155. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  156. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  157. Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults
  158. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey
  159. Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Undergoing Cardioversion of Atrial Fibrillation (From ENSURE-AF)
  160. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  161. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  162. Phytol: A review of biomedical activities
  163. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
  164. Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults
  165. A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study
  166. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  167. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  168. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
  169. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  170. The Yin and Yang of carbon nanomaterials in atherosclerosis
  171. Application of nanotechnology to improve the therapeutic benefits of statins
  172. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
  173. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations
  174. Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES
  175. Effect of statins on toll-like receptors: a new insight to pleiotropic effects
  176. Dietary inflammatory index and cardiometabolic risk in US adults
  177. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
  178. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  179. Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey
  180. Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function
  181. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases
  182. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  183. Alcohol use and attributable disease burden in 195
  184. Modulation of heat shock proteins by statins
  185. Incidence of familial hypercholesterolemia in patients from the tercet registry
  186. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”
  187. Novel Therapeutic Targets for Managing Dyslipidemia
  188. The optimal time of day for statin administration
  189. Serum lipophilic antioxidants levels are associated with leucocyte telomere length among US adults
  190. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines
  191. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?
  192. High density lipoprotein cholesterol and cancer: Marker or causative?
  193. The Role of Nutraceuticals in Statin Intolerant Patients
  194. Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials
  195. Leptin, cardiovascular diseases and type 2 diabetes mellitus
  196. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  197. Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials
  198. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
  199. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry
  200. From meta-analysis to Cochrane reviews
  201. Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults
  202. Phase 3 Evaluation of Bempedoic Acid Added to Ezetimibe in Patients with Elevated LDL-cholesterol Receiving No Greater Than Low Dose Statins: CLEAR Tranquility
  203. PCSK9 genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization study
  204. Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
  205. Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  206. Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length
  207. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015
  208. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40
  209. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
  210. Statin Intolerance
  211. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review
  212. The impact of nuts consumption on glucose/insulin homeostasis and inflammation markers mediated by adiposity factors among American adults
  213. Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases
  214. Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure
  215. Botanicals and phytochemicals active on cognitive decline: The clinical evidence
  216. Evaluation of a dimeric-cRGD peptide for targeted PET-CT imaging of peripheral angiogenesis in diabetic mice
  217. Novel drugs for heart rate control in heart failure
  218. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants
  219. Association between plasma trans fatty acids concentrations and leucocyte telomere length in US adults
  220. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland
  221. The link between insulin resistance parameters and serum uric acid is mediated by adiposity
  222. Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal
  223. IMPACT OF BODY MASS INDEX AND OBESITY ON CLINICAL OUTCOMES IN THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) RANDOMIZED TRIAL
  224. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance
  225. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  226. Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
  227. Management of Statin Intolerance in 2018: Still More Questions Than Answers
  228. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
  229. Complications of Diabetes 2017
  230. Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis
  231. Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: A meta-analysis
  232. HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions
  233. Hypercholesterolaemia – practical information for non-specialists
  234. Natural approaches in metabolic syndrome management
  235. Prevalence of childhood and adolescent overweight and obesity in Asian countries: a systematic review and meta-analysis
  236. Association Between Plasma Trans-Fatty Acid Concentrations and Measures of Glucose Homeostasis and Cardiovascular Risk Factors in Adults in NHANES 1999-2000
  237. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs
  238. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
  239. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
  240. Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease
  241. HDL functionality in type 1 diabetes
  242. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents
  243. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  244. The impact of argan oil on plasma lipids in humans: Systematic review and meta-analysis of randomized controlled trials
  245. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  246. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study
  247. Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans
  248. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  249. Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials
  250. C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US Adults
  251. Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States
  252. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials
  253. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
  254. Optimizing Cholesterol Treatment in Patients With Muscle Complaints
  255. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  256. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction
  257. Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
  258. Usefulness of atherogenic dyslipidemia index to assess the cardiovascular risk of primary care patients – Results from lipidogram 2004 and lipidogram 2006 studies
  259. Lipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004–2010)
  260. The assessment of selected markers of cardiac dysfunction in the analysis of cardiovascular risk in dialysis patients
  261. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  262. Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes
  263. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis
  264. Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
  265. PCSK9 and infection: A potentially useful or dangerous association?
  266. Hypertension - Current Natural Strategies to Lower Blood Pressure
  267. Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia
  268. The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease
  269. Editorial: Natural Products as the Integral Part of the Therapy?
  270. HDL abnormalities in familial hypercholesterolemia: Focus on biological functions
  271. Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study
  272. Statins, haemostatic factors and thrombotic risk
  273. Corrigendum to “Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study” [Int. J. Cardiol. 235 (2017) 11–16]
  274. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  275. Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With HypertensionNovelty and Significance
  276. Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
  277. Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α V β 3 Integrin Activity
  278. Telomere Length Is Associated With Cardiometabolic Factors in US Adults
  279. Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands!
  280. PCSK9 and diabetes: is there a link?
  281. Regulation of PCSK9 by nutraceuticals
  282. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  283. Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults
  284. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
  285. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  286. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials
  287. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  288. Effects of curcumin on HDL functionality
  289. Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study
  290. Accuracy of low-density lipoprotein cholesterol estimation at very low levels
  291. The role of nutraceuticals in the prevention of cardiovascular disease
  292. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
  293. The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients
  294. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials
  295. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials
  296. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
  297. HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  298. EDOXABAN THERAPY INCREASES TREATMENT SATISFACTION AND REDUCES UTILIZATION OF HEALTH CARE RESOURCES: AN ANALYSIS FROM THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) STUDY
  299. Are two drugs better than one? A review of combination therapies for hypertension
  300. The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review
  301. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
  302. Mineral and vitamins consumption is associated with longer telomeres among US adults
  303. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence
  304. Intensive LDL-cholesterol lowering therapy and neurocognitive function
  305. Novel approaches toward the generation of bioscaffolds as a potential therapy in cardiovascular tissue engineering
  306. Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016
  307. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  308. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  309. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease
  310. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?
  311. Association between telomere length and complete blood count in US adults
  312. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
  313. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
  314. Physical Exercise and DNA Injury
  315. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
  316. The association of telomere length and serum 25-hydroxyvitamin D levels in US adults: the National Health and Nutrition Examination Survey
  317. Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk
  318. PCSK9 inhibitors in sepsis: a new potential indication?
  319. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
  320. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
  321. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
  322. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  323. Effects of pentoxifylline on inflammatory markers and blood pressure
  324. Lipid-modifying effects of nutraceuticals: An evidence-based approach
  325. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies
  326. What is the association of lipid levels and incident stroke?
  327. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms
  328. Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm
  329. Polypills for the prevention of Cardiovascular diseases
  330. Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?
  331. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease
  332. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients
  333. Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over
  334. A systematic review and meta-analysis comparing the effects of statins and fibrates on plasma lipoprotein(a) levels
  335. Can the effects of gender, menopause and ageing on lipid levels be differentiated?
  336. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
  337. Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
  338. Complex relationship of obesity and obesity paradox in heart failure – higher risk of developing heart failure and better outcomes in established heart failure
  339. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
  340. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  341. IMPROVE-IT
  342. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  343. Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
  344. Expert opinion: the therapeutic challenges faced by statin intolerance
  345. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial
  346. Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases
  347. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  348. Lipoprotein (a)—We Know So Much Yet Still Have Much to Learn …
  349. THE EFFECT OF QUERCETIN ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  350. Rozpowszechnienie zaburzeń lipidowych w Polsce. Wyniki badania NATPOL 2011.
  351. Erratum to: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
  352. The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
  353. Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
  354. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT
  355. Discussion around statin discontinuation in older adults and patients with wasting diseases
  356. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
  357. Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients
  358. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
  359. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials
  360. Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials
  361. Exosomes as nanocarriers for siRNA delivery: paradigms and challenges
  362. Complications of Diabetes 2016
  363. Evaluation of medical and psychological parameters of quality of life in supraventricular tachyarrhythmia children. A comparison with healthy children
  364. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis
  365. Molecular mechanisms of statin intolerance
  366. Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients
  367. The impact of statin therapy on plasma levels of von Willebrand factor antigen
  368. Sex-dependent differences in obesity indices and inflammatory markers in non-diabetic obese patients
  369. Lipids, blood pressure and kidney update 2015
  370. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
  371. Familial hypercholesterolaemia: A global call to arms
  372. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
  373. Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease
  374. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies
  375. An evaluation of RVX-208 for the treatment of atherosclerosis
  376. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
  377. Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
  378. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study
  379. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients
  380. Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol
  381. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials
  382. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
  383. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease
  384. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations
  385. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
  386. Markers of increased cardiovascular risk in elderly patients with chronic kidney disease: A preliminary study
  387. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials
  388. Strength-endurance training may promote pro-atherogenic changes in lipoprotein profile of adolescent rowers
  389. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension
  390. Is Blood Pressure Control for Stroke Prevention the Correct Goal?
  391. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials
  392. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations
  393. Sudden cardiac death in CKD patients
  394. The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
  395. Lipids, blood pressure and kidney update 2014
  396. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
  397. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge
  398. Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension
  399. Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
  400. In reply—Coenzyme Q10 and Statin-Induced Myopathy
  401. Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
  402. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease
  403. Combination Therapy In Dyslipidemia
  404. Conclusions and Take Home Message
  405. Complications of Diabetes
  406. Statins and Fibrates: Should They Be Recommended?
  407. Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?
  408. Wpływ statyn na majaczenie w następstwie operacji kardiochirurgicznych – dowody z piśmiennictwa
  409. Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients
  410. Association between statin use and plasma D-dimer levels
  411. Effects of Coenzyme Q10 on Statin-Induced Myopathy
  412. Systematic review/Meta-analysis Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials
  413. Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
  414. The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
  415. Club 35 Poster session 3: Friday 5 December 2014, 08:30-18:00 * Location: Poster area
  416. Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function
  417. ETC-1002: A future option for lipid disorders?
  418. Contrasting Cholesterol Management Guidelines for Adults with CKD
  419. Red blood cell transfusion is a determinant of neurological complications after cardiac surgery
  420. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication
  421. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient
  422. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline
  423. Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
  424. Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
  425. Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?
  426. Subfractions and Subpopulations of HDL: An Update
  427. Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density Lipoprotein)
  428. Pre-CKD- Do we Need Another Hero?
  429. Patients with Prehypertension – Do we have Enough Evidence to Treat them?
  430. Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
  431. Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients
  432. Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
  433. Statins and New-Onset Diabetes
  434. Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease
  435. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality
  436. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
  437. The effect of timing of cardiac catheterization on acute kidney injury after cardiac surgery is influenced by the type of operation
  438. Novel anti-obesity drugs and plasma lipids
  439. Bedside Tool for Predicting the Risk of Postoperative Atrial Fibrillation After Cardiac Surgery: The POAF Score
  440. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
  441. Lipid, blood pressure and kidney update 2013
  442. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level
  443. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study
  444. Dysfunctional HDL: the journey from savior to slayer
  445. Editorial: Atrial Fibrillation after Coronary Surgery: The Need for an Effective Pharmacological Prophylaxis
  446. Hypertension and Prevention of Diastolic Heart Failure in the Aging Population
  447. Heart function disturbances in chronic kidney disease – echocardiographic indices
  448. Assessment of the Relationship between Lipid Parameters and Obesity Indices in Non-Diabetic Obese Patients: A Preliminary Report
  449. Aging and Heart Failure
  450. Markers of increased cardiovascular risk in patients with chronic kidney disease
  451. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study
  452. Factors influencing post-coronary artery bypass grafting atrial fibrillation episodes
  453. Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych
  454. Blood Pressure Levels and Stroke: J-curve Phenomenon?
  455. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity
  456. Postępowanie w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych
  457. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?
  458. Heart failure biomarkers in patients with dilated cardiomyopathy
  459. Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events
  460. Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation
  461. The effects of statins on blood pressure in normotensive or hypertensive subjects — A meta-analysis of randomized controlled trials
  462. Rationale of Statin Therapy in Septic Patients
  463. Acute Coronary Syndromes in Patients with Chronic Kidney Disease
  464. Statins in patients with chronic kidney disease – an attempt at recommendations
  465. Medication Management of Chronic Heart Failure in Older Adults
  466. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease
  467. Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
  468. Letter on ‘Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney’
  469. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants
  470. The Knowledge and Awareness of Hypertension Among Patients With Hypertension in Central Poland
  471. New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension
  472. Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum
  473. Statin therapy and new-onset diabetes: an attempt at recommendations
  474. The Role of Fibrate Treatment in Dyslipidemia: An Overview
  475. Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
  476. Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
  477. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
  478. Metabolic syndrome and renal disease
  479. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective
  480. The risk of atherosclerosis in patients with chronic kidney disease
  481. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials
  482. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease
  483. Editorial Statin treatment in the elderly: how much do we know?
  484. Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease
  485. State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology
  486. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology
  487. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up
  488. State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease
  489. Predictors of Insulin Resistance in Patients With Obesity
  490. Prevention of sudden cardiac death in patients with chronic kidney disease
  491. Blood Pressure J-Curve: Current Concepts
  492. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
  493. Renalase, Hypertension, and Kidney — The Discussion Continues
  494. An update on biomarkers of heart failure in hypertensive patients
  495. Observations on Degenerative Changes Within the Optic Nerve in Patients With Primary Open Glaucoma and Arterial Hypertension: 6-Month Follow-Up
  496. Lipids, Blood Pressure, Kidney-what was New in 2012?
  497. Statins and the Risk of Diabetes: The Debate
  498. Statin use and risk of diabetes mellitus in postmenopausal women
  499. The meaning of hypokalemia in heart failure
  500. Preoperative Statin Therapy Is Not Associated With a Decrease in the Incidence of Delirium After Cardiac Operations
  501. Hypertension therapy in the older adults—do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly
  502. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults
  503. Hypertension and kidney disease
  504. Polish Lipid Association – A strong response to the problem of lipid disorders in Poland and Central and Eastern Europe
  505. Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients
  506. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
  507. Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets
  508. Editorial The effects of statins on blood pressure: current knowledge and future perspectives
  509. Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation – a pilot study
  510. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels
  511. Imbalance between pro-angiogenic and anti-angiogenic factors in rheumatic and mixomatous mitral valves
  512. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly
  513. Left atrial size in hypertension and stroke
  514. Statins – Do we really know all mechanisms of action of this group of drugs?
  515. What is the risk of hyperkalaemia in heart failure?
  516. Dronedarone: An overview
  517. Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes
  518. Ventricular Assist Device – How to Obtain Optimal Benefits?
  519. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?
  520. Gender Differences in the Treatment of Ischemic Heart Disease
  521. Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure
  522. Reply to Preoperative n-3 Polyunsatured Fatty Acids Do Not Reduce Postoperative Atrial Fibrillation in Cardiac Surgery, by Takagi I. and Umemoto T
  523. Malignancy-Associated Dyslipidemia
  524. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe
  525. Statins and dilated cardiomyopathy: do we have enough data?
  526. Erythropoietin update 2011
  527. State of the art papers Lipids, blood pressure, kidney – what was new in 2011?
  528. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease
  529. Optimal Timing of Discontinuation of Clopidogrel and Risk of Blood Transfusion After Coronary Surgery
  530. Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm
  531. Relevance of 123 I-BMIPP delayed scintigraphic imaging for patients with angina pectoris – a pilot study
  532. Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
  533. Current Place of Beta-Blockers in the Treatment of Hypertension
  534. Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure
  535. The Use of DSM-IV and ICD-10 Criteria and Diagnostic Scales for Delirium Among Cardiac Surgery Patients: Results From the IPDACS Study
  536. Current problems in hypertension and nephrology
  537. Statins in patients with chronic kidney disease: why, who and when?
  538. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study
  539. Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells
  540. Postoperative Atrial Fibrillation - What Do We Really Know?
  541. Takotsubo cardiomyopathy — The current state of knowledge
  542. Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery
  543. Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial)
  544. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties
  545. Preoperative n-3 Polyunsatured Fatty Acids Are Associated With a Decrease in the Incidence of Early Atrial Fibrillation Following Cardiac Surgery
  546. The role of Toll-like receptors in renal diseases
  547. Are Polymorphisms within Endothelial Nitric Oxide Synthase Good Predictors of Coronary Artery Disease
  548. Left atrial and left atrial appendage systolic function in patients with post-myocardial distal blocks
  549. Editorial Are we getting to lipid targets in real life?
  550. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study
  551. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study
  552. Progression of diabetic retinopathy correlated with muscle perfusion disturbances of the lower limbs, with clinically important diagnostic recommendations
  553. Statin therapy in the elderly: A review
  554. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis
  555. Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery
  556. Vernakalant hydrochloride for the treatment of atrial fibrillation
  557. The Role of Polymorphisms Within Paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the Modulation of Cardiovascular Risk: A Pilot Study
  558. Natriuretic Peptides in Septic Patients
  559. Predictive factors for endoleaks after thoracic aortic aneurysm endograft repair
  560. Lone atrial fibrillation: what do we know?
  561. Role and significance of statins in the treatment of hypertensive patients
  562. Is Polymorphism Within eNOS Gene Associated With the Late Onset of Myocardial Infarction? A Pilot Study
  563. The Clinical Manifestation of Myocardial Infarction in Elderly Patients
  564. Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients With Stable Angina
  565. Nephroprotective and clinical potential of statins in dialyzed patients
  566. The mechanisms of atrial fibrillation in hyperthyroidism
  567. Atrial Fibrillation: The New Epidemic of the Ageing World
  568. HSP 70 and atherosclerosis – protector or activator?
  569. Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model
  570. Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation
  571. The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases
  572. Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension
  573. Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival
  574. The Role of Trimetazidine After Acute Myocardial Infarction
  575. Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model
  576. Detection of infectious agents by polymerase chain reaction in human aortic wall
  577. Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery
  578. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent
  579. Dofetilide for the Prevention of Postoperative Atrial Fibrillation After Coronary Surgery: Is It a Useful Routine Prophylaxis?
  580. Obesity and postoperative atrial fibrillation. Is there no connection?
  581. Statins in the prevention of postoperative atrial fibrillation: Is there really no effect?
  582. Endovascular treatment of mycotic aortic aneurysms
  583. Plasma Total Antioxidant Activity in Comparison With Plasma NO and VEGF Levels in Patients With Metabolic Syndrome
  584. Does Gender Influence the Patency of Infrainguinal Bypass Grafts?
  585. LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN SUBJECTS WITH METABOLIC SYNDROME
  586. Effect of Cardiovascular Drugs on Adenosine Deaminase Activity
  587. Relation Between Postoperative Mortality and Atrial Fibrillation Before Surgical Revascularization - 3-Year Follow-Up
  588. Letter by Banach et al Regarding Article, "Postoperative Treatment With Carvedilol, a β-Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting"
  589. Natriuretic peptides in cardiovascular diseases
  590. Carvedilol modifies antioxidant status of patients with stable angina
  591. Clinical Utility and Use of DSM–IV and ICD–10 Criteria and The Memorial Delirium Assessment Scale in Establishing a Diagnosis of Delirium After Cardiac Surgery
  592. Comparison of Transperitoneal and Retroperitoneal Approaches in Abdominal Aortic Surgery
  593. eComment: The anastomosis between aorta and extension conduit of the pulmonary artery
  594. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation
  595. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement
  596. Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation
  597. Echocardiographic Evaluation of the Left Atrium and Left Atrial Appendage Function in Patients with Atrial Septum Aneurysm - Implications for Thromboembolic Complications
  598. Plasma Endothelin-1 Levels in Septic Patients
  599. 92 Low BMI as an independent risk factor of death in patients with severe heart failure subjected to aortic valve replacement
  600. Atrial and Brain Natriuretic Peptide and Endothelin-1 Concentration in Patients with Idiopathic Arterial Hypertension: The Dependence on the Selected Morphological Parameters
  601. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients
  602. Preoperative predictors of delirium after cardiac surgery: a preliminary study
  603. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment
  604. N-TERMINAL BRAIN NATRIURETIC PROPEPTIDE LEVELS CORRELATE WITH PROCALCITONIN AND C-REACTIVE PROTEIN LEVELS IN SEPTIC PATIENTS
  605. Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention
  606. Risk Factors for Atrial Fibrillation in Adult Patients in Long-Term Observation Following Surgical Closure of Atrial Septal Defect Type II
  607. TNF-α priming effect on polymorphonuclear leukocyte reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients
  608. P3-49
  609. Risk Factors of Atrial Fibrillation Following Coronary Artery Bypass Grafting
  610. Increased Levels of Soluble TNF-α Receptors and Cellular Adhesion Molecules in Patients Undergoing Bioincompatible Hemodialysis